Globus Medical (GMED)
(Delayed Data from NYSE)
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.43 USD
+0.80 (1.10%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $73.40 -0.03 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum C VGM
Zacks News
Globus Medical (GMED) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 24.44% and 10.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Globus Medical (GMED) Could Beat Earnings Estimates Again
by Zacks Equity Research
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
by Zacks Equity Research
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
Medical Products' Aug 4 Earnings Roster: MCK, ABC & More
by Trina Mukherjee
The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
4 Medical Device Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.
Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand
by Zacks Equity Research
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
Exact Sciences (EXAS) Q2 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business sees significant improvement in revenues during the second quarter on Cologuard volume growth.
NuVasive (NUVA) Q2 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
NuVasive (NUVA) reports strong segmental and geographical performance driving the top line in second-quarter 2021.
Integra (IART) Q2 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Integra (IART) reports better-than-expected revenues with strong segmental performance driving the top line in second-quarter 2021.
Globus Medical (GMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
Is a Beat in Store for Zimmer Biomet (ZBH) in Q2 Earnings?
by Zacks Equity Research
Zimmer Biomet's (ZBH) S.E.T. is expected to have performed better than expected on the back of the company's focus on sports and extremities, especially upper extremities, trauma and CMFT.
Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher's (TMO) base business witnesses accelerated growth in the second quarter.
Chemed (CHE) Q2 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings and revenues with strong Roto-Rooter segment performance driving the top line in second-quarter 2021.
Here is Why Growth Investors Should Buy Globus Medical (GMED) Now
by Zacks Equity Research
Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Globus Medical (GMED) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why You Should Invest In Globus Medical (GMED) Now
by Zacks Equity Research
Strong first-quarter performance by the U.S. Spine and Enabling Technologies business contributed to Globus Medical's (GMED) top line.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)
by Zacks Equity Research
LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
With vaccine rollouts through Q2, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered top-line contributions from vaccine and therapy production supplies.
Globus Medical (GMED) Marks New Milestone for ExcelsiusGPS
by Zacks Equity Research
Globus Medical's (GMED) ExcelsiusGPS Robotic Navigation system reaches new surgical milestone for spinal procedures.
Globus Medical (GMED) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Globus Medical (GMED) owing to significant trend improvement and the company's focus on product development.
Why Is Globus Medical (GMED) Down 3.8% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bruker's (BRKR) robust performances across segments and geographies manage to drive its Q1 sales despite pandemic-led business challenges.
Globus Medical (GMED) Moves 5.4% Higher: Will This Strength Last?
by Zacks Equity Research
Globus Medical (GMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.